These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 15687480)
1. Valsartan in chronic heart failure. Ripley TL Ann Pharmacother; 2005 Mar; 39(3):460-9. PubMed ID: 15687480 [TBL] [Abstract][Full Text] [Related]
2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [TBL] [Abstract][Full Text] [Related]
3. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836 [TBL] [Abstract][Full Text] [Related]
4. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651 [TBL] [Abstract][Full Text] [Related]
5. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801 [TBL] [Abstract][Full Text] [Related]
6. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Smith DG; Cerulli A; Frech FH Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995 [TBL] [Abstract][Full Text] [Related]
7. Rationale for angiotensin II receptor blocker therapy in chronic heart failure. Cohn JN J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S38-40. PubMed ID: 17199220 [TBL] [Abstract][Full Text] [Related]
8. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. Cohn JN; Tognoni G; N Engl J Med; 2001 Dec; 345(23):1667-75. PubMed ID: 11759645 [TBL] [Abstract][Full Text] [Related]
9. [Valsartan improves symptoms and quality of life in patients with chronic heart failure]. Baumhäkel M; Müller U; Böhm M MMW Fortschr Med; 2008 Apr; 150 Suppl 1():48-53. PubMed ID: 18540333 [TBL] [Abstract][Full Text] [Related]
10. New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease. Ruilope LM J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S29-31. PubMed ID: 17199217 [TBL] [Abstract][Full Text] [Related]
11. Effects of angiotensin-converting enzyme inhibitor versus valsartan on cellular signaling events in heart transplant. White M; Ross H; Levesque S; Whittom L; Pelletier GB; Racine N; Meloche S; Voisin L Ann Pharmacother; 2009 May; 43(5):831-9. PubMed ID: 19417110 [TBL] [Abstract][Full Text] [Related]
12. A review of the current evidence for the use of angiotensin-receptor blockers in chronic heart failure. Erhardt LR Int J Clin Pract; 2005 May; 59(5):571-8. PubMed ID: 15857354 [TBL] [Abstract][Full Text] [Related]
13. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of valsartan and lisinopril on autonomic nervous system activity in chronic heart failure. De Tommasi E; Iacoviello M; Romito R; Ceconi C; Guida P; Massari F; Francolini G; Bertocchi F; Ferrari R; Rizzon P; Pitzalis MV Am Heart J; 2003 Nov; 146(5):E17. PubMed ID: 14597946 [TBL] [Abstract][Full Text] [Related]
15. A drug safety evaluation of valsartan. Fogari R; Zoppi A Expert Opin Drug Saf; 2011 Mar; 10(2):295-303. PubMed ID: 21142805 [TBL] [Abstract][Full Text] [Related]
16. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294 [TBL] [Abstract][Full Text] [Related]
17. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA; Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343 [TBL] [Abstract][Full Text] [Related]
18. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Philipp T; Smith TR; Glazer R; Wernsing M; Yen J; Jin J; Schneider H; Pospiech R Clin Ther; 2007 Apr; 29(4):563-80. PubMed ID: 17617280 [TBL] [Abstract][Full Text] [Related]
19. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Cohn JN; Anand IS; Latini R; Masson S; Chiang YT; Glazer R; Circulation; 2003 Sep; 108(11):1306-9. PubMed ID: 12939207 [TBL] [Abstract][Full Text] [Related]
20. [Review of randomized trials of angiotensin receptor blockers in the treatment of patients with congestive heart failure]. Rakugi H; Ogihara T Nihon Rinsho; 2001 Oct; 59(10):2051-61. PubMed ID: 11676153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]